EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtVideo/AudioOpen Access

SGLT2 inhibitors and nephrolithiasis risk: a meta-analysis

Mehmet Kanbay iD, Crischentian Brinza, Sidar Copur, Ozge Sekreter, Alexandru Burlacu iD, Katherine R Tuttle iD, Peter Rossing iD, Adrian Covic

Nephrology Dialysis Transplantation · 01.04.2025 · 40 (4) · 671-678

DOI: 10.1093/ndt/gfae179 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 07.08.2024. Verfasst von Mehmet Kanbay und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Nephrology, Koç University School of Medicine, Istanbul, Turkey. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Nephrolithiasis, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NIDDK NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sodium–glucose co-transporter 2 (SGLT2) inhibitors are novel anti-diabetic medications with potential beneficial effects on cardiovascular and renal outcomes, metabolic parameters and body weight. In addition to the beneficial effects on renal function, including estimated glomerular filtration rate and reduction in proteinuria, recent studies have investigated the potential role of SGLT2 inhibitor (SGLT2i) therapy on nephrolithiasis development. Nephrolithiasis, a condition affecting almost 10% of the general population at least once during a lifetime, is a common disorder with considerable risk for acute and chronic kidney injury and relatively few effective therapeutic options.

Methods

We performed a literature search through multiple databases, including PubMed, Ovid MEDLINE, Web of Science, Scopus and Cochrane Library. We followed the systematic review and meta-analysis guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. We included a total of 11 635 698 patients who experienced nephrolithiasis from six clinical trials in this meta-analysis study.

Results

In the pooled analysis, nephrolithiasis occurred in 1.27% of patients in the SGLT2i group (n = 739 197), compared with 1.56% of patients (n = 10 896 501) in the control arm (active control, placebo or no therapy). SGLT-2 inhibitor therapy has been associated with a lower risk for nephrolithiasis compared with placebo {odds ratio [OR] 0.61 [95% confidence interval (CI) 0.53–0.70], P < .00001} or active therapy such as glucagon-like peptide 1 and dipeptidyl peptidase 4 inhibitors [OR 0.66 (95% CI 0.47–0.93), P = .02].

Conclusion

We demonstrated a lower risk of nephrolithiasis with SGLT2i therapy compared with placebo or active control. Potential underlying mechanisms include osmotic diuresis leading to a reduction in the concentration of lithogenic substances, anti-inflammatory and anti-fibrotic effects and an increase in urine pH. There is a clear need for future large-scale randomized clinical trials evaluating such associations for better understanding.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2NephrolithiasisSodium-Glucose Transporter 2 InhibitorsHumansGlomerular Filtration RatePrognosisRisk Factors

Stichwörter der Autor:innen

calcium oxalateglucosurianephrolithiasisosmotic diuresissodium–glucose co-transporter 2 inhibitors

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, Division of Nephrology, Koç University School of Medicine, Istanbul, Turkey.
  • Faculty of Medicine, Grigore T Popa University of Medicine and Pharmacy, Iasi, Romania.
  • Institute of Cardiovascular Diseases 'Prof. Dr George I.M. Georgescu', Iasi, Romania.
  • Department of Internal Medicine, Koç University School of Medicine, Istanbul, Turkey.
  • Department of Medicine, Koç University School of Medicine, Istanbul, Turkey.
  • Division of Nephrology, University of Washington, Seattle, WA, USA.

ORCID-Profile: Mehmet Kanbay, Alexandru Burlacu, Katherine R Tuttle, Peter Rossing

Förderung

  • NIH HHS
  • NIDDK NIH HHS
  • NHLBI NIH HHS
  • Centers for Disease Control
  • NCATS NIH HHS
  • Doris Duke Charitable Foundation
  • NIMHD NIH HHS
  • Travere Therapeutics

Zitieren

APA

Kanbay, M., Brinza, C., Copur, S., Sekreter, O., Burlacu, A., Tuttle, K. R., Rossing, P., & Covic, A. (2025). SGLT2 inhibitors and nephrolithiasis risk: a meta-analysis. Nephrology Dialysis Transplantation, 40(4), 671-678. https://doi.org/10.1093/ndt/gfae179

Vancouver

Kanbay M, Brinza C, Copur S, Sekreter O, Burlacu A, Tuttle KR, et al. SGLT2 inhibitors and nephrolithiasis risk: a meta-analysis. Nephrology Dialysis Transplantation. 2025;40(4):671-678. doi:10.1093/ndt/gfae179

BibTeX
@article{Kanbay2025,
  author = {Kanbay, Mehmet and Brinza, Crischentian and Copur, Sidar and Sekreter, Ozge and Burlacu, Alexandru and Tuttle, Katherine R and Rossing, Peter and Covic, Adrian},
  title = {SGLT2 inhibitors and nephrolithiasis risk: a meta-analysis},
  journal = {Nephrology Dialysis Transplantation},
  year = {2025},
  volume = {40},
  number = {4},
  pages = {671--678},
  doi = {10.1093/ndt/gfae179}
}
Kostenlos starten →